These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33141944)

  • 41. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive socioeconomic and clinical profiles of antidepressant response and remission.
    Jain FA; Hunter AM; Brooks JO; Leuchter AF
    Depress Anxiety; 2013 Jul; 30(7):624-30. PubMed ID: 23288666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressants for people with epilepsy and depression.
    Maguire MJ; Marson AG; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early symptom change prediction of remission in depression treatment.
    Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
    Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EEG microstates as markers of major depressive disorder and predictors of response to SSRIs therapy.
    Lei L; Liu Z; Zhang Y; Guo M; Liu P; Hu X; Yang C; Zhang A; Sun N; Wang Y; Zhang K
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110514. PubMed ID: 35085607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.
    Papakostas GI; Stahl SM; Krishen A; Seifert CA; Tucker VL; Goodale EP; Fava M
    J Clin Psychiatry; 2008 Aug; 69(8):1287-92. PubMed ID: 18605812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
    Silverstone PH; Entsuah R; Hackett D
    Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks.
    Naito M; Kato M; Koshikawa Y; Bandou H; Sakai S; Takekita Y; Nishida K; Kinoshita T
    J Affect Disord; 2022 Oct; 314():27-33. PubMed ID: 35798178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
    Agid O; Lerer B
    Int J Neuropsychopharmacol; 2003 Mar; 6(1):41-9. PubMed ID: 12899735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
    Fava M; Thase ME; DeBattista C
    J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor.
    Fujita M; Richards EM; Niciu MJ; Ionescu DF; Zoghbi SS; Hong J; Telu S; Hines CS; Pike VW; Zarate CA; Innis RB
    Mol Psychiatry; 2017 May; 22(5):754-759. PubMed ID: 27725657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.